Session 3: Monitoring TFR and Ph+ ALL
Chair: Dr Naranie Shanmunagathan

• Monitoring TFR - Challenges 
  (A/Prof Susan Branford)
• Ph+ ALL
  (Dr David Yeung)

Monitoring TFR - Challenges
A/Prof. Susan Branford, SA Pathology / Universities of Adelaide and South Australia

• The new frontier for CML is reaching a deep molecular response
• Close molecular monitoring is required after TKI cessation to monitor for molecular response
• Appropriate molecular monitoring of TFR
• Important issues for monitoring patients who have ceased therapy
• What molecular facts influence the chance of achieving TFR?
• Next generation sequencing projects for mutation discovery
• NGS at blast crisis plus RNA-seq plus CNV
• What we know so far. What we don't know.
• CML Genomics Alliance

PH+ALL
Dr David Yeung - SAHMRI / Royal Adelaide Hospital

• Cytogenetic basis of ALL
• Poor prognosis in pre-imatinib era
• Choice of TKI
• Elderly / unfit patients
• Young / fit patients - chemotherapy intensity reduction
• Patient case
• BCR-ABL like ALL